Pa Shun International Holdings (HKSE:00574) Risk Assessment

View and export this data going back to 2015. Start your Free Trial

What is Pa Shun International Holdings Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Pa Shun International Holdings is: No Data: Cannot be evaluated.

Competitive Comparison of Pa Shun International Holdings's Risk Assessment

For the Pharmaceutical Retailers subindustry, Pa Shun International Holdings's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pa Shun International Holdings's Risk Assessment Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Pa Shun International Holdings's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Pa Shun International Holdings's Risk Assessment falls into.

Pa Shun International Holdings (HKSE:00574) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Pa Shun International Holdings Risk Assessment Related Terms

Thank you for viewing the detailed overview of Pa Shun International Holdings's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Pa Shun International Holdings (HKSE:00574) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Pa Shun International Holdings Ltd (HKSE:00574) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

229 Wufuqiao East Road, No. 608-616, Building 28, Longfor North Paradise Walk 2, Jinniu District, Sichuan Province, Chengdu, CHN

Website

http://www.pashun.com.cn

Pa Shun International Holdings Ltd is an investment holding company engaged in the manufacturing and distribution of pharmaceutical products. The business activity of the group is operated through Pharmaceutical distribution and Pharmaceutical manufacturing segment. Geographically all the activities are carried out in the PRC. The company derives the majority of revenue from the Pharmaceutical distribution segment which include sales of pharmaceutical products to wholesalers, franchise retail pharmacy chain stores and hospitals and other medical institutions in rural areas.

Executives

Zhongtai International Asset Management (singapore) Pte. Ltd.	2102 Investment manager
Arab Osman Mohammed	2104 Agent
Lai Wing Lun	2104 Agent
Win Win Stable No.3 Fund Sp	2106 Person having a security interest in shares
Zhongtai Innovation Capital Management Limited	2102 Investment manager
Chen Yenfei	2101 Beneficial owner
Praise Treasure Limited	2101 Beneficial owner

Pa Shun International Holdings (HKSE:00574) Headlines

No Headlines